Where can I buy genuine Erdafitinib in China?

Erdafitinib (Erdafitinib) has been officially launched in China, but due to its short time on the market, market circulation channels are still being gradually established. Common specifications include 5mg 28 tablets, 3mg 56 tablets, 4mg*28 tablets, etc., which are currently not included in the scope of medical insurance reimbursement, so there is still great pressure on the economic level. If domestic patients want to purchase genuine erdafitinib, there are usually three ways:

First of all, it can be purchased through the pharmacies of some large tertiary hospitals. These hospital pharmacies will give priority to original drugs that have been approved for marketing. However, due to limited supply in the early stages of marketing, patients in some areas may face temporary shortages or queues.

Secondly, regular pharmacies in Hong Kong are also an important way to obtain erdafitinib. The original drugs on the Hong Kong market are consistent with international standards and the quality of the drugs is guaranteed. However, due to factors such as tariffs and transportation costs, the prices are usually slightly higher than in the mainland. This type of channel is suitable for patients who have higher requirements for drug formality.

Third, overseas generic drug versions are gradually entering patients’ horizons. Currently common imitation versions mainly come from Laos and Bangladesh. The active ingredients and dosage of these generic drugs are basically the same as those of the original drugs, but the price is much lower. For example, the price of a box of generic versions may be only a fraction of that of the original drugs. This price advantage is significant for patients who require long-term use. However, it needs to be emphasized that generic drugs must be purchased through formal channels to avoid drug quality risks caused by unknown sources.

In terms of use, the main indication of erdafitinib is the treatment of patients with locally advanced or metastatic bladder cancer with FGFR gene mutations. Especially after failure of platinum-based chemotherapy, erdafitinib can be used as a subsequent treatment option. It inhibits the FGFR pathway and cuts off the signaling mechanism that cancer cells rely on to survive, thereby achieving the goal of inhibiting tumor development.

Reference materials：https://www.balversa.com/